Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
Technology appraisal
Reference number: TA978
Published:
The company has requested a delay to the evidence submission for this appraisal, therefore we will be terminating this topic ID number in line with receipt of the MA and a new topic ID will be scheduled and communicated to stakeholders